CHOSA Oncology invites investors to two upcoming presentations
Summary
CHOSA Oncology invites investors to two June presentations in Stockholm and Copenhagen to discuss its precision oncology platform and recent clinical progress. The company says it is raising capital through a directed issue that will initially bring in about SEK 3.4 million before costs. CHOSA highlights its Cisplatin-DRP biomarker, which aims to identify patients most likely to respond to cisplatin or carboplatin. The company also points to positive carboplatin data, ongoing research, and its broader plan to partner or sublicense LiPlaCis and the DRP technology.
Funding
Amount
None
Total raised
Date
June 9, 2025
Announcement date
Investors
-
Lead investors
Company
chosa.bio
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected